NASDAQ$PSNL
Personalis Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported record revenue and achieved twentieth consecutive quarter of growth.
Personalis, Inc. reported record quarterly revenue of $21.7 million, an 11% increase compared to the second quarter of 2020. Revenue from biopharma and all other customers grew 72% over the same period of the prior year.
- Record quarterly revenue of $21.7 million, an 11% increase year-over-year.
- Revenue from biopharma and all other customers, excluding VA MVP, increased 72% year-over-year.
- Achieved milestone of delivering more than 125,000 whole human genome sequences to the VA MVP.
- NeXT Personal, Personalis' Minimal Residual Disease (MRD) offering, remains on-track for launch in 2021.
Headline financials
Revenue & EPS history
Personalis · Revenue · Quarterly
$21.7M
Revenue by segment
Personalis · $18.2M total across 4 segments · Q3 2023
- Pharma tests and services$8M—43.8%
- Enterprise sales$7.81M—42.8%
- Population sequencing$2.4M—13.2%
- Other$38K—0.2%
Forward guidance
Personalis expects total revenue for Q3 2021 to be approximately $22.2 million and a net loss in the range of $17 million to $18 million. For the full year of 2021, Personalis expects total revenue to be approximately $85 million and a net loss in the range of $65 million to $70 million.
Tailwinds
- Total revenue to be approximately $22.2 million for Q3 2021
- Revenue from biopharma and all other customers, excluding VA MVP, to be in the range of $7.5 million to $8.5 million for Q3 2021
- Total revenue to be approximately $85 million for the full year of 2021
- Revenue from biopharma and all other customers, excluding VA MVP, to be in the range of $33 million to $34 million for the full year of 2021
- Estimated outstanding shares of 44 million
Headwinds
- Net Loss to be in the range of $17 million to $18 million for Q3 2021
- Net Loss to be in the range of $65 million to $70 million for the full year of 2021
- Timing and pace of new orders from customers, including from the U.S. Department of Veterans Affairs Million Veteran Program
- Timing of tissue, blood, and other specimen sample receipts from customers, which can materially impact revenue quarter over quarter and year over year
- Ongoing COVID-19 pandemic, which may significantly impact the company’s business and operations and the business and operations of our customers and suppliers
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+1.0%
Avg return
Earnings day
+1.5%
Avg return
5 days after
+1.5%
Avg return
30 days after
59%
16 / 27 earnings
Positive
+19.9%
Q1 2025
Best reaction
-23.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.2% | -0.7% | +76.6% | |
| Q4 2025 | +0.6% | -1.1% | -29.8% | |
| Q3 2025 | -12.3% | -1.1% | +9.5% | |
| Q1 2025 | +19.9% | +27.5% | +30.3% | |
| Q4 2024 | -2.4% | +5.9% | -14.6% | |
| Q3 2024 | -23.4% | -12.8% | -26.4% | |
| Q2 2024 | +7.2% | +34.7% | +67.8% | |
| Q1 2024 | +4.4% | -2.5% | -14.6% | |
| Q4 2023 | +3.3% | +16.0% | -0.7% | |
| Q3 2023 | +10.4% | -3.8% | +39.6% | |
| Q2 2023 | +4.7% | +7.9% | -17.9% | |
| Q1 2023 | +4.5% | +3.2% | -6.4% | |
| Q4 2022 | -7.2% | -5.3% | -18.2% | |
| Q3 2022 | -1.5% | -15.3% | +4.7% | |
| Q2 2022 | +10.6% | +11.1% | -21.4% | |
| Q1 2022 | -7.2% | -24.8% | -34.1% | |
| Q4 2021 | +12.2% | +11.0% | -14.4% | |
| Q3 2021 | +2.6% | -5.4% | -38.9% | |
| Q2 2021 | +10.2% | +4.1% | +12.4% | |
| Q1 2021 | -0.6% | -9.9% | -4.3% | |
| Q4 2020 | -11.1% | -10.8% | -36.3% | |
| Q3 2020 | +0.1% | -0.3% | +13.6% | |
| Q2 2020 | -2.4% | -3.7% | -4.7% | |
| Q1 2020 | +4.6% | +7.2% | +27.6% | |
| Q4 2019 | +17.5% | +27.5% | +52.8% | |
| Q3 2019 | +0.2% | -12.7% | +0.3% | |
| Q2 2019 | -15.6% | -6.2% | -11.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro